このエントリーをはてなブックマークに追加
ID 58279
JaLCDOI
フルテキストURL
Thumnail 74_2_179.pdf 1.93 MB
著者
Abe, Yoshiyuki Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine
Fujibayashi, Kazutoshi Medical Technology Innovation Center, Juntendo University
Nishizaki, Yuji Medical Technology Innovation Center, Juntendo University
Yanagisawa, Naotake Medical Technology Innovation Center, Juntendo University
Nojiri, Shuko Medical Technology Innovation Center, Juntendo University
Kon, Takayuki Department of Internal Medicine and Rheumatology, Juntendo University Nerima Hospital
Tada, Kurisu Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine
Yamaji, Ken Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine
Tamura, Naoto Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine
抄録
Glucocorticoids (GCs) have long played a central role in the treatment of systemic lupus erythematosus (SLE), but these drugs have many adverse effects. We will determine whether rapid weekly GC tapering is non-inferior to conventional biweekly tapering in patients with severe SLE. This is a randomized, open-label, multicenter controlled trial. The primary outcome is the relapse-free survival rate at 52 weeks. The main secondary outcome is the prevalence of the Lupus Low Disease Activity State at 52 weeks. The trial will determine the optimal method of tapering GCs in patients with severe SLE.
キーワード
systemic lupus erythematosus
relapse-free survival rate
glucocorticoid, tapering
Lupus Low Disease
Activity State
Amo Type
Clinical Study Protocol
発行日
2020-04
出版物タイトル
Acta Medica Okayama
74巻
2号
出版者
Okayama University Medical School
開始ページ
179
終了ページ
183
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
著作権者
CopyrightⒸ 2020 by Okayama University Medical School
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Science KeyUT